Daewoong completes EMA application of ‘Nabota’

‘Nabota,’ a Daewoong Pharmaceutical’s botulinum toxin, will enter the European market.

EVOLUS, a European partner of Nabota, said it has completed a process of the marketing authorization application(MAA) of DWP-450(Nabota’s development name in the U.S. and Europe) as a forehead wrinkle removal for adults at the European Medicines Agency.

The MAA was based on a result of randomized, multi-cen...